Haus of Marin
Haus of Marin · 29 1st Street · Corte Madera, CA 94925
5.0· 125 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
Haus of Marin is a medical spa in Corte Madera, California. Its website lists Botox, fillers, PRP, facials and weight-loss treatments, and describes regenerative skin treatments that are performed without surgery and typically done as a series of sessions spaced several weeks apart. Hormone care is also listed for the practice. On Google it holds a 5.0-star rating across 125 reviews dating back to 2023, with 41 posted in the past year. Reviewers most often mention the staff and the team's knowledge, and 13 reviews mention results.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-24. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 125 Google reviews. Of the 100 reviews we analyzed, 98 (98%) are positive (4–5★) and 2 (2%) are negative (1–2★).
What patients like
- Friendly, helpful staff28 reviews
- Knowledgeable, professional providers20 reviews
- Weight-loss results13 reviews
- Feeling listened to8 reviews
Common complaints
Very few complaints — only 2 negative reviews, with no recurring theme.
Most recent Google reviews
Caitlin M.★★★★★2026-09-24The Haus team is incredible! I see Chloe and am consistently impressed by her thoughtfulness, expertise, and follow-up. She stays up to date on all the latest techniques and products so I don’t have to, and she has a sophisticated understanding of how different treatments work together to create the best overall result. I've never had a practitioner take such care post-treatment to ensure I'm happy and that everything looks just right. Thank you, Chloe + Haus!
Judith A.★★★★★2026-09-24I’ve trusted RN Chloe with my skin care for several years, and I couldn’t be happier. Her thoughtful assessments and knowledge about treatment options, together with her skill and attentive care, have left my skin looking fresher and more radiant than I could have imagined at my age. I feel fortunate to be in her expert hands!
Katy B.★★★★★2026-09-24Chloe has been doing my Botox for years and honestly, she’s the best! She is an absolute angel of a nurse who is gentle, caring, funny & so smart. She has also done my lip filler and I’m planning to start microneedling with her soon as well.
Jill F.★★★★★2026-09-04These guys are amazing! They are super knowledgeable and excellent at what they do.
Megan W.★★★★★2026-08-29Haus of Marin is amazing! It has such a great vibe and the kindest people!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs